HiberCell

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. The company focuses on developing therapeutics aimed at preventing cancer relapse and metastasis, addressing critical mechanisms that contribute to treatment resistance and cancer-related mortality. HiberCell's innovative therapeutic pipeline targets adaptive stress pathways and immune modulation, leveraging advanced artificial intelligence and machine learning to analyze multi-omic and phenotypic tumor profiles. This approach aims to generate insights that connect these profiles to clinical outcomes, ultimately enabling patients to achieve longer, cancer-free lives. The company is supported by a group of visionary investors in the biotechnology sector who share a commitment to transforming the treatment of metastatic and relapsed cancer.